Pharmacoeconomic Guidelines: Israel
Country/Region: Israel
Submission Guidelines
Guidelines for submitting a pharmaceutical product in the National List of Health Services in Israel - 2022 (PDF in Hebrew)
Submission Guidelines Source:
State of Israel Ministry of Health
https://www.gov.il/he/Departments/publications/reports/hbs2022
Additional Information:
Guidelines for submitting other technologies to the National List of Health Services in Israel - 2022 PDF in Hebrew
Information current as of Tuesday, July 26, 2022
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | Submission Guidelines |
| Title and year of the document | Guidelines for submitting a pharmaceutical product in the National List of Health Services in Israel - 2022 |
| Affiliation of authors | Pharmacoepidemiology and Pharmacoeconomics Department, Pharmaceutical Administration of the Ministry of Health |
| Purpose of the document | Submission for a listing of new drug products |
| Standard reporting format included | Yes |
| Disclosure | Not stated |
| Target audience of funding/ author's interests | Pharmaceutical companies, Pharmacoepidemiology and Pharmacoeconomics Department, Pharmaceutical Administration of the Ministry of Health |
| Perspective | Sick Funds of the National Health Insurance |
| Indication | Yes |
| Target population | Yes |
| Subgroup analysis | Not stated |
| Choice of comparator | Not specific, all alternatives |
| Time horizon | Not stated |
| Assumptions required | Not stated |
| Preferred analytical technique | Cost effectiveness evaluation |
| Costs to be included | Treatment costs, resources to support therapy and treat side effects and treatment failures |
| Source of costs | Ministry of Health’s ambulatory services’ price |
| Modeling | Yes, requires details |
| Systematic review of evidences | Yes |
| Preference for effectiveness over efficacy | Not stated |
| Preferred outcome measure | Final outcomes |
| Preferred method to derive utility | Not stated |
| Equity issues stated | Not stated |
| Discounting costs | Not stated |
| Discounting outcomes | Not stated |
| Sensitivity analysis-parameters and range | Impact of the uncertainty of the different data on the strength of the assessments. |
| Sensitivity analysis-methods | Not stated |
| Presenting results | Not stated |
| Incremental analysis | Not stated |
| Total costs vs effectiveness (cost/effectiveness ratio) | Not stated |
| Portability of results (Generalizability) | Yes |
| Financial impact analysis | Yes, first three years following the inclusion. |
| Mandatory or recommended or voluntary | |
Acknowledgement:
Dan Greenberg, PhD, Professor, School of Public Health, Ben-Gurion University of the Negev highly contributed to the key feature form